Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations

Blood

Volumn 91, Issue 6, 1998, Pages 2054-2061

  Svenson, Morten ^a   Hansen, Morten Bagge ^a   Ross, Christian ^a   Diamant, Marcus ^a   Rieneck, Klaus ^a   Nielsen, Henrik ^a   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; NORDIMMUN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFECTION; INFLAMMATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032521450     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.6.2054.2054_2054_2061     Document Type: Article

References (47)

1. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107, 1992
2. Smiley JD, Talbert MG: Southwestern internal conference: High-dose intravenous gamma globulin therapy: How does it work? Am J Med Sci 309:295, 1995
3. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV: V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev 139:79, 1994
4. Bendtzen K, Hansen MB, Ross C, Svenson M: Cytokine autoantibodies, in Peter JB, Shoenfeld Y (eds): Autoantibodies. Amsterdam, Elsevier Science, 1996, p 209
5. Svenson M, Hansen MB, Bendtzen K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 92:2533, 1993
6. Hansen MB, Svenson M, Abell K, Yasukawa K, Diamant M, Bendtzen K: Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 25:348, 1995
7. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 95:1974, 1995
8. Garrone P, Djossou O, Fossiez F, Reyes J, Ait-Yahia S, Maat C, Ho S, Hauser T, Dayer JM, Greffe J, Miossec P, Lebecque S, Rousset F, Banchereau J: Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitor. Mol Immunol 33:649, 1996
9. Hansen MB, Svenson M, Bendtzen K: Human anti-interleukin 1α antibodies. Immunol Lett 30:133, 1991
10. Svenson M, Nedergaard S, Heegaard PMH, Whisenand TD, Arend WP, Bendtzen K: Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur J Immunol 25:2842, 1995
11. Kharazmi A, Svenson M, Nielsen H, Birgens HS: Effect of cyclosporin A on human neutrophil and monocyte function. Scand J Immunol 21:585, 1985
12. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor I. N Engl J Med 327:28, 1992
13. Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 79:3101, 1992
14. Huizinga TW, Dolman KM, van der Linden NJ, Kleijer M, Nuijens JH, von dem Borne AE, Roos D: Phosphatidylinositol-linked FcRIII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol 144:1432, 1990
15. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R: Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor. Mol Immunol 29:633, 1992
16. Ragnhammar P, Friesen HJ, Frödin JE, Lefvert AK, Hassan M, Osterborg A, Mellstedt H: Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84:4078, 1994
17. Coutinho A, Kazatchkine MD, Avrameas S: Natural autoantibodies. Curr Opin Immunol 7:812, 1995
18. Hansen MB, Andersen V, Rohde K, Florescu A, Ross C, Svenson M, Bendtzen K: Cytokine autoantibodies in rheumatoid arthritis. Scand J Rheumatol 24:197, 1995
19. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095, 1996
20. Menetrier-Caux C, Briere F, Jouvenne P, Peyron E, Peyron F, Banchereau J: Identification of human IgG autoantibodies specific for IL-10. Clin Exp Immunol 104:173, 1996
21. Prümmer O, Bunjes D, Wiesneth M, Hertenstein B, Arnold R, Porzsolt F, Heimpel H: Antibodies to interferon-α: A novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant 17:617, 1996
22. Jouvenne P, Fossiez F, Garrone P, Djossou O, Banchereau J, Miossec P: Increased incidence of neutralizing autoantibodies against interleukin-1α (IL-1α) in nondestructive chronic polyarthritis. J Clin Immunol 16:283, 1996
23. Fomsgaard A, Svenson M, Bendtzen K: Auto-antibodies to tumour necrosis factor α in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol 30:219, 1989
24. Peichl P, Ceska M, Broell H, Effenberger F, Lindley IJD: Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann Rheum Dis 51:19, 1992
25. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D: Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88:410, 1996
26. Galley P, Mach J-P, Carrel S: Characterization and detection of naturally occurring antibodies against IL-1α and IL-1β in normal human plasma. Eur Cytokine Netw 2:329, 1991
27. Sylvester I, Yoshimura T, Sticherling M, Schröder JM, Ceska M, Peichl P, Leonard EJ: Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest 90:471, 1992
28. Tiberio L, Carus A, Pozzi A, Rivoltini L, Morelli D, Monti E, Balsari A: The detection and biological activity of human antibodies to IL-2 in normal donors. Scand J Immunol 38:472, 1993
29. Sioud M, Dybwad A, Jespersen L, Suleyman S, Natvig JB, Forre O: Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-α): In vitro function and precise epitope mapping by phage epitope library. Clin Exp Immunol 98:520, 1994
30. Trotter JL, Damico CA, Trotter AL, Collins KG, Cross AH: Interleukin-2 binding proteins in sera from normal subjects and multiple sclerosis patients. Neurology 45:1971, 1995
31. Leusch H-G, Sitzler G, Markos-Pusztai S: Failure to demonstrate TNFα-specific autoantibodies in human sera by ELISA and Western blot. J Immunol Methods 139:145, 1991
32. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD: Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 79:2946, 1992
33. Hansen MB, Svenson M, Abell K, Varming K, Nielsen HP, Bertelsen A, Bendtzen K: Sex-and age-dependency of IgG autoantibodies against IL-1α in healthy humans. Eur J Clin Invest 24:212, 1994
34. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K: Increased in vivo antibody activity against interferon α, interleukin-1α, and interleukin-6 after high-dose Ig therapy. Blood 90:2376, 1997
35. Sedmak JJ, Grossberg SE: High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-β produced in yeast. J Interferon Res 9:S61, 1989 (Suppl)
36. Varki A: Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:97, 1993
37. Svenson M, Hansen MB, Kayser L, Rasmussen AK, Reimert CM, Bendtzen K: Effects of human anti-IL-1α autoantibodies on receptor binding and biological activities of IL-1. Cytokine 4:125, 1992
38. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Ragnhammar P, Mellstedt H, Thorpe R: Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 104:351, 1996
39. Bendtzen K, Svenson M, Jønsson V, Hippe E: Autoantibodies to cytokines - friends or foes? Immunol Today 11:167, 1990
40. Klein B, Brailly H: Cytokine-binding proteins: Stimulating antagonists. Immunol Today 16:216, 1995
41. Moore MAS: The clinical use of colony stimulating factors. Annu Rev Immunol 9:159, 1991
42. Santiago-Schwarz F, Divaris N, Kay C, Carsons SE: Mechanisms of tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-induced dendritic cell development. Blood 82:3019, 1993
43. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
44. Chen TT, Levy R: Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J Immunol 154:3105, 1995
45. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA: Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88:202, 1996
46. Grau GE, Kindler V, Piguet PF, Lambert PH, Vassalli P: Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation. J Exp Med 168:1499, 1988
47. Tiegs G, Barsig J, Matiba B, Uhlig S, Wendel A: Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J Clin Invest 93:2616, 1994